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Abstract
Background: Randomised controlled trials (RCTs) are perceived as the gold-standard method for
evaluating healthcare interventions, and increasingly include quality of life (QoL) measures. The
observed results are susceptible to bias if a substantial proportion of outcome data are missing. The
review aimed to determine whether imputation was used to deal with missing QoL outcomes.
Methods: A random selection of 285 RCTs published during 2005/6 in the British Medical Journal,
Lancet, New England Journal of Medicine and Journal of American Medical Association were
identified.
Results: QoL outcomes were reported in 61 (21%) trials. Six (10%) reported having no missing
data, 20 (33%) reported ≤ 10% missing, eleven (18%) 11%–20% missing, and eleven (18%) reported
>20% missing. Missingness was unclear in 13 (21%). Missing data were imputed in 19 (31%) of the
61 trials. Imputation was part of the primary analysis in 13 trials, but a sensitivity analysis in six. Last
value carried forward was used in 12 trials and multiple imputation in two. Following imputation,
the most common analysis method was analysis of covariance (10 trials).
Conclusion: The majority of studies did not impute missing data and carried out a complete-case
analysis. For those studies that did impute missing data, researchers tended to prefer simpler
methods of imputation, despite more sophisticated methods being available.
Background
Randomised controlled trials (RCTs) are perceived as the
gold-standard evaluation method for evidence based
medicine. Increasingly quality of life (QoL) outcomes are
measured in clinical trials of new treatments, as this is
becoming an important factor in decision making. Com-
mon QoL instruments include the generic questionnaires
such as SF12/SF36 [1] or the shorter EuroQoL EQ5D [2].
Where appropriate, disease specific questionnaires may
also be included. Often these outcomes are collected via
postal questionnaires and consequently subject to a cer-
tain amount of missing data. This can lead to a potential
bias in the results if the missing data are not adequately
handled. Often assumptions are made about the missing-
ness, which may or may not be appropriate.
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Trials 2008, 9:51 http://www.trialsjournal.com/content/9/1/51Missing QoL data can be very informative in its own right.
QoL data is a subjective patient reported outcome which
perhaps makes it more sensitive than other outcomes to
missing data assumptions. The data may be missing
because a patient is not well enough to complete ques-
tionnaires or take part in interviews. Disregarding those
patients without QoL information is likely to bias the
results, affect trial conclusions and ultimately clinical
practice. Therefore, it is important to make use of as much
data as possible from as many patients as possible.
There are many ways researchers deal with missing data.
For example complete-case analysis, available case analy-
sis, joint modelling, pattern mixture models and the focus
in this paper – imputation. Simple imputation is a process
whereby a reasonable alternative value is substituted for
one that is missing. Common procedures include last
value carried forward (LVCF), regression and mean impu-
tation. Both regression and mean imputation can be
undertaken at a population level or specific to an individ-
ual. A more sophisticated approach is multiple imputa-
tion, which imputes several values, creating several
datasets. Each dataset is analysed separately and the
results are combined [3]. The current literature recom-
mends this over simple imputation [4,5] but researchers
may overlook its advantages as simple imputation is eas-
ier to implement.
A brief overview of some methods for missing data is pro-
vided and is by no means exhaustive. The aim of this
review was to identify the imputation methods (if any)
currently adopted by researchers analyzing and reporting
the results of clinical trials with regard to the quality of life
outcomes. This review was undertaken as part of a larger
project and hence restricted to QoL outcomes in RCTs.
Issues surrounding missing data will be similar in other
studies and for other types of outcomes.
Missing data theory
Missingness mechanism
In any study there will be reasons why data are missing,
which may or may not be related to the outcome of inter-
est. The main mechanisms for missing data are described
in detail, in Little and Rubin [3]. In simple terms, missing
completely at random (MCAR) is where the missingness
is unrelated to outcome (past, present or future). Missing
at random (MAR) can be assumed if the missingness is
related to observed data (outcome or other collected
data). Finally missing not at random (MNAR) occurs if
missingness is associated with unobserved data. There are
two broad types of missingness pattern: monotone and
non-monotone (intermittent). Monotone (or terminal)
missing data occurs when responses are provided at every
assessment until a given time and thereafter missing.
Non-monotone occurs if missing data occurs in between
observed assessments.
Analysis methods
One way to deal with missing data is to ignore it com-
pletely and undertake a complete-case analysis. This
method is the easiest to perform, but has the potential to
remove a large portion of the patients from the analysis.
This method has two major disadvantages in that it
reduces the sample size (and thus power of study) and
additionally may produce biased results unless the data
are MCAR, which may be an unrealistic assumption. An
alternative is available case analysis, and in a longitudinal
setting one example is repeated measures ANOVA, which
assumes MAR data. All patients who provide at least one
outcome measure of a series can be included. This
increases the size of sample for the analysis. Specific treat-
ment differences at a given time point can be calculated
using the data available. Other options for model-based
methods include joint modelling, selection models, or
pattern mixture models [6,7], the details of which out
with the scope of this paper.
Imputation
Under simple imputation a single alternative value is sub-
stituted for a missing value. This is followed by a com-
plete-case analysis strategy on the augmented dataset.
Examples of simple imputation strategies are last value
carried forward (LVCF), mean imputation (calculated on
observed data), hotdeck (random selection from those
observed) and regression (using other variables in the
dataset) [8,9]. Multiple imputation is a process where sev-
eral values (e.g. five) are imputed to create multiple data-
sets [3]. The chosen analysis method is performed on each
dataset and the results combined. The advantages are that
it has the ability to perform complete-case analysis but
reflects the uncertainty of the imputed value. In addition,
the accuracy of the standard errors is improved. With the
advances in computer software, multiple imputation can
easily be carried out. In the statistical software package
SAS use PROC MI (to carry out imputation) and PROC
MIANALYZE (to combine results) or within STATA use
the ICE command. Theoretically, multiple imputation
methods can handle MAR and MNAR. In the case of
MNAR, the dropout process can be modelled and incor-
porated into the MI procedure. However, this model can-
not be verified (since required data are missing) and the
analysis is quite sensitive to the dropout model. There-
fore, most of the MI procedures require the MAR assump-
tion [10]. Several approaches can be used for MI including
regression, propensity scoring or Monte Carlo Markov
Chain (MCMC) imputation [11,12]. The choice between
these depends on your variable type (continuous, ordinal
or nominal) and pattern of missingness (monotone or
non-monotone).Page 2 of 6
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A PubMed search was carried out to identify RCTs pub-
lished during 2005 and 2006 in the four leading medical
journals: BMJ, Journal of the American Medical Associa-
tion (JAMA), Lancet and New England Medical Journal
(NEMJ). A random selection of a half was sought from the
articles identified. The focus of the review was 'imputation
to deal with missing QoL outcomes', therefore only those
studies which included QoL outcomes were considered
for further investigation.
Data extraction
Data extraction was a two-stage process. During the first
stage information on each RCT included: outcome and
type (primary and QoL); single or repeated endpoints;
amount of missing information; was imputation used;
was the mechanism of missingness discussed. Data extrac-
tion of each study was undertaken by a single researcher,
with queries resolved by consulting a second reviewer. To
assess consistency between reviewers' two papers were
doubly abstracted by all reviewers. No inconsistencies
were shown.
Once those articles with QoL outcomes were identified, a
second more detailed data abstraction was undertaken.
This obtained more detailed information with regard to
missing data and how it was dealt with. Information col-
lected at stage two included: Study details – type of study,
study setting, treatments, number of participants and
patient demographics (age, gender etc); Proportion of
missing outcome data in each treatment arm; Is analysis
complete case analysis or do they account for missing data
either with modelling or imputation for the primary end-
point; Analysis method used for primary analysis – e.g.
repeated measures ANOVA; Imputation details – what
method, effect on analysis (sensitivity analysis); Is missing
data mechanism identified.
Results
The literature search described above produced 568 arti-
cles for potential inclusion. Following a process of ran-
dom selection, 285 (50%) articles reporting RCTs during
2005 and 2006 were identified. A QoL outcome (primary
or secondary) was reported in 61 papers (21%) and form
the basis of this review. The majority of these were pub-
lished in the BMJ (n = 27, 44%) with 17 (28%) published
in NEJM, ten (16%) in the Lancet and the remaining seven
(12%) in JAMA.
Description of missing data
Table 1 describes the proportion of missing data split
between studies which did and did not employ imputa-
tion. Of the 42 studies that did not perform imputation
techniques, six did not provide enough information to
determine the proportion of missing cases. Of the remain-
ing, 36, 16 studies had less than 10% missing data in the
primary QoL endpoint. This is in contrast to the 5 of 19
studies that used an imputation method. Of the remain-
ing 14 studies which used imputation, the proportion of
missing data was unclear for six.
Current CONSORT guidelines [13] for the reporting of
RCTs require authors to provide a flow diagram of partic-
ipants in the trial. This should detail the withdrawals and
reasons for withdrawal. The majority of trials (n = 50,
82%) contained within this review did provide the flow
diagram and reasons for missingness such as withdrawal,
death or other medical problems. However, there was no
detailed discussion of these reasons and the impact they
may have had on the analysis and subsequent results. In
only one study, the mechanism of missingness was dis-
cussed and was found to be non-ignorable [14].
QoL measures used
The range of QoL measures used in trials covered by this
review was considerable. Nine different generic QoL
measures were utilised including: General Health Ques-
tionnaire (GHQ) – seven trials; SF12/SF36 – 14 trials;
WHOQOL – one trial; Global assessment of functioning
(GAF) – one trial; EuroQoL EQ5D – five trials. Due to the
differing disease areas the sample of trials covered, there
were a large number of disease specific measures used.
Examples included: Asthma QoL score, dermatology life
index, rhinoconjunctivitis QoL measure, irritable bowel
disease questionnaire (IBDQ), Alzheimer's Disease
Assessment Scale and the Oswestry pain score. The post
treatment follow up using these QoL measures ranged
from one to five assessments, with the majority being col-
lected within twelve months.
Imputation
Nineteen (31%) of the 61 trials used some form of impu-
tation. For a description of these 19 studies see additional
file 1: Description of trials with imputation of quality of
life outcomes. Thirteen studies undertook imputation in
the primary analysis [14-26]. Seven of these studies
Table 1: Proportion of missing data within the 61 studies with 
QoL outcomes
Number of Studies
Proportion of 
missing data
No imputation Imputation Total
None 6 0 6
< 10% 16 5 21
11–20% 6 5 11
>20% 8 3 11
Unclear 6 6 12
Total 42 19 61Page 3 of 6
(page number not for citation purposes)
Trials 2008, 9:51 http://www.trialsjournal.com/content/9/1/51employed the imputation method LVCF [LOCF]
[15,17,19,21,23-25]. Berry et al. [16] used a combination
or worst value imputation and LVCF. The worse value
observed in the sample was imputed if missingness was
known to be due to asthma. If missingness was unrelated
to asthma LVCF was used. Hseih et al., [20] carried for-
ward the baseline QoL value to the post treatment and six
month follow up assessment. Buszewicz et al. [18]
employed hotdeck imputation for missing baseline values
and multiple imputation (using a predictive model) for
the missing follow up scores. Kennedy et al. [22] imputed
missing scores based on changes in other items when at
least 75% of those items were present (such as IBS severity
scale). Petersen et al. [14] used a projection method
appropriate for assessing responses among subjects with
neurodegenerative disease. In the remaining study, that
employed imputation as part of the primary analysis, the
imputation method was not specified, only that it was
undertaken [26].
Six trials reported results after imputation as a sensitivity
analysis. LVCF was used by four studies [27-30] and of
these Peterson et al. [29] also considered imputing a zero
value for those that were missing and McManus et al. [27]
evaluated the use of the mean of the series. Fairbank et al.
[31] employed multiple imputation using a regression
model as part of a sensitivity analysis. Hunkeler et al. [32]
mentioned they used imputation in a sensitivity analysis
but did not specify which method.
The imputation process described above relates to missing
form imputation, namely the whole QoL measure. The
QoL instruments are made up of items which contribute
to the score. In the case of the EQ5D measure if one of the
five items is missing, the overall health status score cannot
be calculated. However, in the SF36 if at least half the
items in a scale are provided, the mean of the observed
items is imputed for the missing items, allowing the scale
score to be calculated. In the trials contained within this
review, item imputation was not discussed, so it is possi-
ble this process was carried out, reducing the amount of
missing data reported.
Analysis methods
In those studies where imputation was not used (42 tri-
als), the method of analysis was unclear in three cases
(7%). A complete case analysis was undertaken in 30 of
42 trials (71%). The methods of complete-case analysis
were: t-test (11 trials); analysis of variance (ANOVA) (one
trial); analysis of covariance (ANCOVA) (13 trials); gen-
eral linear model (one trial); Mann-Whitney test (four tri-
als). For those studies not undertaking a complete-case
analysis, a repeated measures approach was used by nine
trials (22%) with eight using a linear mixed model for
those patients with at least baseline data, thus allowing for
some missing values in follow up data. In the ninth trial
area under the curve (AUC) was used for analysis.
Following imputation 10 of 19 trials used ANCOVA, two
used regression, two trials used a general linear model,
two a t-test, one used generalised estimating equations,
one a stratified rank test and finally one used a repeated
measures model. All of the studies which employed impu-
tation collected data for repeated assessments, but only
four of the 19 trials used a repeated measures analysis.
Discussion
This review has highlighted the need to take more account
of missing data when analysing QoL outcomes in an RCT.
The majority of trials identified the number of patients
used in analysis by use of a flow diagram, as required by
the CONSORT guidelines [13]. Half of the trials with a
QoL outcome performed complete case analysis. There
was no detailed discussion of the impact this had on the
analysis and bias contained within the reported results.
Complete case analysis is easy to perform, but has the
potential to remove a large portion of the patients from
the analysis. This method has two major disadvantages in
that it reduces the sample size (and thus power of study)
and may produce biased results unless the data are MCAR.
Mixed model analysis assumes MAR data, however this
assumption was not discussed by any of the authors
which undertook this method of analysis.
A fifth of the articles sampled contained a QoL outcome,
with nearly 31% of these performing an imputation pro-
cedure. The rationale behind the choice of imputation
method was not discussed by any of articles. The review
showed that of those choosing to carry out imputation,
LVCF was popular. However, this method makes the
assumption that the outcome is unchanged with time and
in QoL situations this is unlikely. In some studies, you
might carry forward an off-treatment score to an on-treat-
ment missing value which is not likely to be that reflective
the truth. As Gadbury states '...although intuitively
appealing, LOCF [LVCF] requires restrictive assumptions
to produce valid statistical conclusions' [5]. Carpenter and
Kenward (2007) agree with this conclusion and provide a
thorough critique of LOCF [LVCF] [33], warning against
its use.
The results of this review support the conclusions of a
review by Wood et al., [34] which considered primary out-
comes irrespective of type. LVCF was popular with only
one trial using multiple imputation. Despite the advances
in available software [12] and recommendations against
LVCF [33], the researchers involved in RCTs tend to prefer
this simple method.Page 4 of 6
(page number not for citation purposes)
Trials 2008, 9:51 http://www.trialsjournal.com/content/9/1/51Conclusion
Researchers involved with the design and analysis of clin-
ical trials should take the following into consideration.
Ideally one should aim to avoid missing data at the outset
though often this is impossible. The data collection
method should be chosen with the aim of reducing as far
as possible missing data. The reasons why data are missing
should be recorded where possible.
There should be a clearer reporting of the methods used
and the amount of missing data, which should be
described separately for each treatment arm. The impact
the missing data potentially has on results should always
be discussed and a sensitivity analysis provided. Where
imputation is chosen, the reason for the choice of method
should be given. LVCF is usually not recommended,
except in the generally implausible situation where out-
come is not changing over time. Under MAR, it is desira-
ble to include all longitudinal follow up data on the
primary response, up to the end point analysis [33].
Resources that may assist researchers in deciding on
appropriate action for missing data in RCTs include the
recently published book by Molenberghs and Kenward
(2007). The website http://www.lshtm.ac.uk/msu/miss
ingdata/ and complementary monograph 'Missing Data
in randomised controlled trials – a practical guide' [33]
produced as part of an Economic and Social Research
(ESRC) – Research Methods Programme. These resources
will provide many helpful hints, an introduction to theory
and further references that may be useful.
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